LLY · News · 20261112N
Revenue Concentration - Key Products
ELI LILLY & Co · 2026-11-12 · Importance 56 · Surprise 24
Mounjaro and Zepbound, Lilly’s tirzepatide therapies for type II diabetes and obesity, account for around 65% of total company revenue. The report says demand and adoption for both products are rising rapidly. Foundayo, Lilly’s oral GLP-1 obesity treatment launched in April 2026, recorded $281 million in sales in 2026 to date.
Key facts
- Mounjaro and Zepbound account for around 65% of Eli Lilly's total revenues. source